NORTH AFRICA NON-INVASIVE PRENATAL TESTING MARKET ANALYSIS

North Africa Non-Invasive Prenatal Testing MarketSize and Trends

Noninvasive prenatal testing (NIPT) is an evolving screening procedure for pregnant women. It examines cell free Deoxyribonucleic Acid (DNA) of both fetus and the mother. It provides an analysis of genetic screening using only one tube blood. NIPT provides predictions about the absence or presence of genetic abnormality in the fetus. It involves a simple method of blood withdrawal but presents high quality effectiveness for the detection of trisomy by minimizing the number of performing further invasive testing procedures. NIPT is performed to detect certain genetic abnormalities such as missing or extra copies of X and Y chromosomes, trisomy 18, trisomy 13, and Down syndrome. With technological advancements in the near future, NIPT will be able to detect other genetic abnormalities.

North Africa non-invasive prenatal testing market is estimated to be valued at US$ 2,796 million in 2021 and is expected to exhibit a CAGR of 8.7% over the forecast period (2021-2028).

Figure 1. North Africa Non-invasive Prenatal Testing Market Share (%), By Application, 2021

The increasing adoption of inorganic strategies such as strategic collaborations is expected to drive the growth of North Africa non-invasive prenatal testing market over the forecast period.

For instance, in June 2017, Illumina, Inc., an American company, collaborated with Next Generation Genomic Co., Ltd., the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science. This alliance will allow large patient access to Illumina under next-generation sequencing for NIPT.